STEMMERETTIGHEDER OG SELSKABSKAPITAL
| SELSKABSMEDDELELSE nr. 33 - 30. april 2024 |
Efter gennemførsel af kapitalnedsættelsen meddelt 16. april 2024 er det samlede antal stemmerettigheder og den samlede kapital i DFDS A/S pr. dags dato som følger:
Selskabskapital (DKK): 1.159.391.940
Antal aktier: 57.969.597
Antal stemmer*: 57.969.597
*hver aktie a nominelt DKK 20 giver én stemme på generalforsamlingen. Egne aktier er inkluderet i totalerne ovenfor.
I henhold til kapitalmarkedslovens § 32 er DFDS A/S forpligtet til særskilt at meddele det samlede antal stemmerettigheder og den samlede kapital i selskabet ved udgangen af hver kalendermåned, hvori en ændring har fundet sted.
Kontakt
Søren Brøndholt Nielsen, IR +45 33 42 33 59
Om DFDS
Vi driver et transportnetværk i og omkring Europa med en omsætning på DKK 28 mia. og 14.000 heltidsansatte.
Vi transporterer varer i trailere med færge, vej og jernbane samt tilbyder komplementære og relaterede transport- og logistikløsninger.
Vi transporterer også passagerer i bil og til fods med færger på korte ruter og på ruter med overnatning.
DFDS blev grundlagt i 1866, har hovedkontor og er børsnoteret i København.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release
Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued
INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 202420.5.2024 23:00:00 CEST | Press release
Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery
Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release
Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s
Medarbejdervalgt bestyrelsesmedlem Berit Kjerulf er død20.5.2024 18:12:43 CEST | pressemeddelelse
Selskabsmeddelelse for ROCKWOOL A/S Meddelelse nr. 25 – 2024 til Nasdaq Copenhagen 20. maj 2024 Medarbejdervalgt bestyrelsesmedlem Berit Kjerulf er død Det er med stor sorg, at vi meddeler, at ROCKWOOL medarbejder og bestyrelsesmedlem Berit Kjerulf og hendes mand er omkommet i en brand i deres hjem i Jylland i weekenden. Medarbejderne i ROCKWOOL valgte Berit Kjerulf til at repræsentere dem i bestyrelsen i 2022. Berit har været ansat i ROCKWOOL siden 2005. Hun og hendes mand efterlader sig to voksne børn. Bestyrelsesformand Thomas Kähler udtaler, "Berit var et værdsat medlem af ROCKWOOL familien, en højt værdsat medarbejder og et hårdtarbejdende medlem af bestyrelsen. Det er svært at beskrive den følelse af sorg, hendes bortgang skaber. På vegne af bestyrelsen og alle vores kolleger udtrykker jeg vores dybeste medfølelse til Berit’s børn og hendes kære. Vi vil naturligvis gøre alt, hvad vi kan for at støtte Berit’s familie og vores kolleger i den kommende tid”. Vi vil informere om Berit